Clinical Trial: 18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: 18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects With Repetitive Brain Trauma at High Risk for Chronic Traumatic Encephalopathy
Brief Summary: This study will explore the use of 18F-AV-1451 as a biomarker for chronic traumatic encephalopathy (CTE) and examine the relationship between clinical presentation and tau deposition.
Detailed Summary:
Sponsor: Avid Radiopharmaceuticals
Current Primary Outcome:
- CTE Biomarker Analysis [ Time Frame: Up to 105 minutes post injection ]18F-AV-1451 uptake and florbetapir F 18 standard uptake value ratio (SUVR) will be compared in subjects with a high risk of CTE and controls.
- Relationship Between Clinical Presentation and Tau Deposition [ Time Frame: Up to 105 minutes post injection ]The relationship among 18F-AV-1451 uptake, florbetapir SUVR, and measurements including neuropsychological assessment battery (NAB) List and Story Learning tests, Trail Making Test - Parts A and B, Wisconsin Card Sorting Test, Wechsler Adult Intelligence Scale - Revised (WAIS-R), Animal Fluency, NAB Naming Test, NAB Map Reading Test and Mini-Mental State Examination (MMSE).
Original Primary Outcome:
- CTE Biomarker Analysis [ Time Frame: Up to 100 minutes post injection ]18F-AV-1451 uptake and florbetapir F 18 standard uptake value ratio (SUVR) will be compared in subjects with a high risk of CTE and controls.
- Relationship Between Clinical Presentation and Tau Deposition [ Time Frame: Up to 100 minutes post injection ]The relationship among 18F-AV-1451 uptake, florbetapir SUVR, and measurements including neuropsychological assessment battery (NAB) List and Story Learning tests, Trail Making Test - Parts A and B, Wisconsin Card Sorting Test, Wechsler Adult Intelligence Scale - Revised (WAIS-R), Animal Fluency, NAB Naming Test, NAB Map Reading Test and Mini-Mental State Examination (MMSE).
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Avid Radiopharmaceuticals
Dates:
Date Received: March 4, 2014
Date Started: June 2014
Date Completion:
Last Updated: February 8, 2017
Last Verified: February 2017